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Summary 
Three primary isoforms of the dimeric glycolytic enzyme, triosephosphate isomerase (TPI; EC 5.3.1.1), are 
detected in proliferating human cells. The electrophoretically separable isoforms result from the three 
possible combinations of constitutive subunits and subunits expressed only in proliferating cells. Only a 
single primary isoform is observed in quiescent cells. The two subunits, which differ by covalent modification 
(s), are products of the single structural locus for this enzyme. Expression of the proliferation specific subunit 
(TPI-2) is detected within 6--10 hr following mitogen stimulation of quiescent human cells, requires RNA 
synthesis and is inhibited by agents which inhibit interleukin 2 expression or function. Only the constitutive 
subunit (TPI-1) is detected in proliferating cells from nonhominoid primate species. A single class of TPI 
mRNA, which is increased > 10 fold following stimulation of quiescent cells, is detected on northern blot 
analysis and S1 nuclease digestion analysis of RNA from quiescent and proliferating human cells. It is similar 
in size to the TPI mRNA from proliferating cells of the African green monkey, a primate species not 
expressing TPI-2. Comparison of the structure of the TPI gene from rhesus monkey (nonexpressing species) 
to the gene from expressing species does not suggest a mechanism for generating TPI-2. Thus, the regulation 
of the expression of the hominoid restricted, proliferation specific subunit of TPI has been further defined, 
although the mechanism for generating TPI-2 remains elusive. 
Introduction 
Cells, as they progress through the cell cycle, ex- 
press specific genes including oncogenes [1-5], 
growth factors [6, 7] and several enzymes and other 
gene products [8-14]. Some of these variably ex- 
pressed genes, such as the oncogenes and growth 
factors, are believed to have a direct role in the 
regulation of cellular proliferation, while other 
gene products have a role in sustaining the cellular 
functions necessary for competence, progression 
and cell division. Definition of the regulation as 
well as the mechanism(s) of variable gene expres- 
sion is crucial to understanding cellular growth and 
proliferation. 
Triosephosphate isomerase (TPI; EC 5.3.1.1) 
exhibits a unique cell cycle dependent expression. 
This enzyme is a dimeric, glycolytic enzyme with a 
high catalytic efficiency [15] and a very slow rate of 
evolution [16]. It is a prevalent protein, present in 
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all cells examined from a wide range of species [17, 
18]. TPI activity increases when mammalian cells 
are stimulated to proliferate and in proliferating 
hominoid cells, a second, electrophoretically-dis- 
tinct subunit of TPI (TPI-2) is synthesized [13, 19- 
22]. Genetic evidence demonstrates that TPI-2 is a 
product of the same structural locus as the constitu- 
tive subunit, TPI-1 [19, 23]. This is consistent with 
the molecular data that indicates the existence of 
only a single functional TPI locus and that it is 
located on human chromosome 12 [24]. Three pos- 
sible combinations of primary subunits, TPI-1/1, 
TPI-1/2 and TPI-2/2, are observed in proliferating 
cells; the level of the TPI 2/2 isozyme consitutes less 
than 5% of the total TPI activity and therefore is 
difficult to detect, even in very rapidly dividing 
cells. The subunits have similar molecular weights, 
but the TPI-2 subunit is more acidic (covalent mod- 
ification of - 4  charge units) and more thermo- 
labile than TPI-1 [19, 25]. The expression of TPI-2 
is not a post-translational event [20] and requires 
both RNA and protein synthesis [21]. The expres- 
sion of TPI-2 is seemingly unique among examples 
of expression of alternative isozymes or isoforms !n 
that the second subunit is expressed only in prolif- 
erating cells and only in the cells of hominoid spe- 
cies [17, 26]. Thus TP1, a constitutively expressed 
housekeeping enzyme exhibiting unique prolifer- 
ation specific expression, provides an interesting 
system for the study of the regulation of gene ex- 
pression. 
We have examined TPI-2 appearance, as well as 
the increase in TPI mRNA and total TPI enzyme 
activity, in mitogen stimulated human peripheral 
lymphocytes and growth arrested human fibro- 
blasts. Selected cell cycle inhibitors were used to 
further define the signals for and timing of the 
appearance of TPI-2. 
Methods 
Cell culture - f ibroblas ts  
The human diploid dermal fibroblast line, GM10, 
(12 fetal weeks) was obtained from Dr. J. Thoene 
(Dept. of Pediatrics, Univ. of Michigan) and main- 
tained in RPMI 1640 (Gibco, Chagrin Falls, OH) 
supplemented with 10% fetal calf serum (Gibco), 
50 units/ml penicillin plus 50/zg/ml streptomycin 
(Gibco) and 2mM glutamine (Sigma, St. Louis, 
MO). Cells were split 1:3 at confluency (0.25% 
trypsin (Sigma) in phosphate buffered saline 
(PBS)) into 75 cm 2 culture flasks. Fibroblast cells 
were growth arrested by 11 days of incubation in 
media containing 0.25% fetal calf serum. This time 
period of incubation was necessary for the reduc- 
tion of the TPI activity because of the 28-30 hour 
half life of TPI [20]. Cells were re-stimulated with 
20% fetal calf serum, with or without various inhib- 
itors [dexamethasone (DEX, 0.1 mM, Sigma), hy- 
droxyurea (HU, l mM, Sigma), and 5-fluorouri- 
dine (FU, 0.2 mM, Calbiochem, San Diego, CA)] 
for indicated times, harvested, washed with PBS, 
and stored as pellets at -70 ° C. 
Cell culture - l ymphocy tes  
One unit of whole blood was collected from volun- 
teer donors into ACD anticoagulant. The blood 
was centrifuged at 2000 rpm for 10 minutes at room 
temperature. The buffy coat was removed, diluted 
with PBS supplemented with 0.1% glucose, lay- 
ered over Histopaque-1077 (Sigma), and centri- 
fuged at 1400 rpm for 30 minutes at room temper- 
ature. The isolated lymphocytes were washed in 
mitogen-free media (RPMI 1640, 20% fetal calf 
serum, 50 units/ml penicillin plus 50/xg/ml strepto- 
mycin and 2 mM glutamine) and counted. Cell re- 
covery was 1.4 + 0.5 x 10 6 cells per ml whole 
blood. 
Lymphocytes were seeded at 1-2 x 106 cells/ml 
into the above media containing 20 mg/ml phytohe- 
magglutinin-M (PHA, Difco, Detroit, MI) and/or 
20ng/ml phorbol 12-myristate 13-acetate (TPA, 
Sigma). Cells were stimulated/inhibited for indicat- 
ed times, harvested, washed with PBS, and stored 
as pellets at -70  ° C. 
Protein~enzyme determinat ions 
Cell extracts were obtained by freeze/thawing as 
described by Decker and Mohrenweiser [19]. The 
supernatants were stored at -70  ° C. Total protein 
was determined using the BioRad Protein Assay 
Kit [27]. TPI, lactate dehydrogenase (LDH, E.C. 
1.1.1.27), and glucosephosphate isomerase (GPI, 
E.C. 5.3.1.9) enzyme activities were determined as 
described by Fielek and Mohrenweiser [28]. Units 
of activity are/xmol of product formed per minute. 
The relative distribution of the activity in the TPI 
1/1 and TPI 1/2 isozymes was assessed by staining 
native polyacrylamide gels as described by Decker 
and Mohrenweiser [17]. Approximately equal units 
of total TPI activity were routinely loaded in each 
lane of the gels. Each gel was stained for several 
time periods to ensure that the relative staining 
intensity of each isozyme was a measure of relative 
differences in enzyme activity. 
RNA determinations 
RNA was extracted from frozen cell pellets of pe- 
ripheral human lymphocytes, PHA stimulated hu- 
man lymphocytes, human lymphoblasts, human fi- 
broblasts and .African green monkey kidney fibro- 
blasts (vero, from M. Levine, Department of 
Human Genetics, University of Michigan) in gua- 
nidinium isothiocyanate as described by Manitias et 
al. [29]. RNA concentration was determined by 
spectrophotometric measurements. 
Total glyoxal treated RNA [30] was used for 
both dot blot and northern blot analyses. Total 
RNA was electrophoretically separated and then 
transferred to GeneScreenPlus as recommended 
by Du Pont New England Nuclear (Boston, MA). 
The northern and dot blots were hybridized with a 
nick translated human TPI cDNA probe 
(pHTP15a) [31], a gift of Dr. L. Maquat, Dept. of 
Human Genetics, Roswell Park Memorial Insti- 
tute, Buffalo, New York. 
S1 nuclease experiment 
A probe was constructed from the human TPI 
cDNA clone. The 936 bp EcoRI fragment corre- 
sponding to the entire TPI coding region (718 bp), 
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except for 32 bp of the 3' end of the coding region 
and including 218 bp of the pKT218 vector (see Fig. 
2 of reference 31 for a detailed restriction site map 
of the cDNA) was the probe. This probe extends 
into exon 7 (the most 3' exon) of the gene, thus it 
covers all of the known intron/exon junctions of the 
human gene [24]. The fragment was isolated from 
low melting point agarose (BRL) by melting the 
agarose at 60°C and then extracting the sample 
several times with an equal volume of phenol fol- 
lowed by ethanol precipitation. 
The EcoRI fragment was dephosphorylated with 
calf intestinal alkaline phosphatase (BRL), then 
labeled using T4 polynucleotide kinase (BRL) and 
g-32p-ATP (Amersham, Arlington Heights, IL). 
This labeled fragment was hybridized to 10/xg of 
each of various total RNA samples at 57 ° C over- 
night in 80% formamide. The duplex was then 
digested with S1 nuclease (Promega) as described 
by Weaver and Weissman [32]. Briefly, 30 units of 
$1 nuclease was added to the DNA - RNA hybrid- 
ization mix and incubated for 30 minutes at 37 ° C. 
Nucleic acids were precipitated from the hybrid- 
ization mixture, resuspended in 80% formamide, 
denatured (3 minutes at 90 ° C) and separated on a 
denaturing (6M urea) 6% polyacrylamide gel 
(1500 volts for 3-8 hours). After electrophoresis, 
an autoradiogram of the gel was made by an over- 
night exposure at -70 ° C. 
Results 
Time course of TPI-2 appearance 
The time course of appearance of TPI-2 and the 
role of several cellular growth factors in regulating 
TPI-2 activity were studied in human fibroblasts. 
An erythrocyte hemolysate and lysates from prolif- 
erating human lymphyblastoid cells and African 
green monkey kidney fibroblasts were routinely 
included as reference samples in each isozyme 
analysis. Two differences in the isozyme pattern 
are noteworthy in comparing the human samples in 
lanes 1 and 5 of Fig. 1. The four additional bands of 
TPI activity migrating immediately anodal of the 
primary TPI 1/1 isozyme band in the erythrocyte 
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Fig. 1. Time course of TPI-2 appearance following serum stimulation of human fibroblasts. Human fibroblasts were rendered quiescent 
by serum deprivation for 11 days. The fibroblasts were restimulated by the addition of serum. Cell extracts were electrophoresed on a 
native polyacrylamide gel, which was then stained for TPI activity. Lane 1 - erythrocyte hemolysate standard, lane 2 -  log phase human 
fibroblasts, lane 3 - human fibroblasts following 11 days of serum deprivation, lane 4 - serum restimulated quiescent human fibroblasts 
(24hr), lane 5 - human lymphoblast,  lane 6 - vero fibroblast. 
sample are the isozyme forms generated via the 
spontaneous deamidation of the two labile aspara- 
gine residues in each subunit [33]. Only the first of 
the deamidation products is marginally detectible 
Table 1. Enzyme activity in serum deprived human fibroblasts 
Days in 0.25% FCS Activity a 
TPI LDH GPI 
0 1.964 0.035 0.010 
5 1.342 0.016 0.006 
11 0.652 0.008 0.003 
10 hrs in 20% FCS b 0.960 0.017 0.006 
48 hrs in 20% FCS b 1.510 0.021 0.008 
a ~mol  product formed/min/107 cells. 
b Cells had been grown in 0.25% FCS for 11 days before the 
addition of fresh media containing 20% FCS. FCS = Fetal Calf 
Serum; TPI = Triosephosphate Isomerase; L D H =  Lactate 
Dehydrogenase; GPI = Glucosephosphate Isomerase. 
in the proliferating lymphoblast sample. The sec- 
ond observation is the existence of a prominent 
isozyme (designated TPI 1/2) in the lymphoblastoid 
cell sample that does not comigrate with any of the 
isozyme forms of the erythrocyte sample. An addi- 
tional, more anodal migrating isozyme can be de- 
tected in human lymphoblastoid cell samples if the 
staining time is increased (see Fig. 1 of reference 
17). The isozyme ratio (TPI 1/1 to TPI 1/2) shifted 
during the period necessary for the cells to reach 
quiescence, with most of the residual activity asso- 
ciated with the TPI 1/1 isozyme in confluent fibro- 
blasts maintained in 0.25% FCS for 11 days (lanes 2 
and 3). The deamidated forms of the enzyme are 
also more prominent in the lysate from the quies- 
cent cells. The level of total TPI activity was re- 
duced to 30% of the initial activity during this 
interval (Table 1). As both TPI-1 and TPI-2 have 
the same rates of degradation [20], the change in 
isozyme profile reflects the continued synthesis of 
TPI-1, while TPI-2 synthesis was 'turned off' dur- 
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Fig. 2. Time cour,;e of  TPI-2 appearance in st imulated lymphocytes.  Peripheral h u m a n  lymphocytes were st imulated with phytohe-  
magglutinin (PHA) .  Cell extracts were electrophoresed through a non-denatur ing gel and the gel was stained for TPI activity. A. Lane  1 
- erythrocyte hemolysate  s tandard,  lane 2 -  0 hours  after P H A  addition, lane 3 - 6 hours  after P H A  addition, lane 4 - 1 2  hours  after P H A  
addition, lane 5 - 24 hours  after P H A  addition, lane 6 - 66 hours  after P H A  addition, lane 7 - vero fibroblast, lane 8 - human  
lymphoblast  r B. Lane  1 -  0 hours  after P H A  addition, lane 2 - 1 2  hours  after P H A  addition, lane 3 - 24 hours  after P H A  addition, lane 4 -  
48 hours  after P H A  addition, lane 5 - 48 hours  unst imulated,  lane 6 - human  lymphoblast ,  lane 7 - veto fibroblast. 
TPI-1, while TPI-2 synthesis was 'turned off' dur- 
ing this time period. Stimulation of the quiescent 
fibroblasts by the addition of medium containing 
20% FCS resulted in a two to three fold increase in 
total TPI activity (Table 1) and increased promi- 
nence of the TPI 1/2 isozyme within 24 hours (Fig. 
1, lanes 3 and 4). No indication of a proliferation 
specific isozyme is observed in proliferating fibro- 
blasts from the African green monkey (vero) (lane 
6). 
Purified growth factors have been reported to 
stimulate an increase in TPI activity in quiescent rat 
cells [34]. A 50-80% increase in TPI activity was 
observed when quiescent human fibroblast cells 
were stimulalLed with fibroblast growth factor 
(FGF) or epidermal growth factor (EGF) (data not 
shown), while, as noted above, the TPI activity was 
increased 2.5 times at 24 hours and 3-fold at 48 
hours following stimulation with FCS. Thus, FGF 
and EGF were much less effective than 20% FCS in 
stimulating the increase in TPI activity in serum 
deprived human fibroblasts. The FGF and EGF 
stimulated increase in TPI activity was also associ- 
ated primarily with the TPI-2 subunit. 
TPI-2 activity was detectable by 6 hours and 
constituted a significant portion of the total TPI 
activity by 18 hours following PHA stimulation of 
human peripheral lymphocytes (Fig. 2). Equal 
amounts of total TPI activity were loaded in each 
lane in Fig. 2, thus, the apparent decline of the TPI 
1/1 isozyme reflects TPI-2 synthesis and the in- 
creased contribution of TPI-2 to the total TPI activ- 
ity rather than a decrease in the TPI 1/1 activity. 
The ratio of the activity associated with the TPI 
heterodimer (TPI 1/2) to the TPI 1/1 homodimer 
following 48 hours of PHA stimulation of lympho- 
cytes (Fig. 2b lane 4) was approximately 1:1. This 
was similar to the relative distribution of the two 
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isoforms observed in a rapidly dividing human lym- 
phoblast cell line (TK6) (Fig. 2b lane 6 or lane 5 of 
Fig. 1). TPI 1/2 was barely visible in lymphocytes 
after 48 hours in RPMI media supplemented with 
FCS, but without the addition of mitogen (Fig. 2b 
lane 5). The isozyme distribution in these cells was 
similar to that observed at the initiation of the 
incubation (Fig. 2b lane 1). 
Increased TPI activity, expressed on a per cell 
basis, was detected at 6-8 hours after initiation of 
stimulation and continued to increase for the dura- 
tion of the experiment (Table 2), attaining a level 
three to four fold over TPI activity in non-stimulat- 
ed lymphocytes. The basal level of activity in non- 
stimulated cells was approximately 5 × 10 -7 units/ 
cell. TPI activity increased to 18 × 10 -7 units/cell at 
48 hours after PHA addition. While TPI enzyme 
activity per cell increased during this time, enzyme 
activity per/zg of total cellular protein remained 
relatively constant after an initial increase occuring 
within the first 6-8 hours of mitogen stimulation. 
Thus, the increase in TPI activity was similar to the 
increase of total protein observed in these cells. 
The changes in GPI and LDH enzyme activities 
followed the same pattern as TPI activity; they 
began to increase 6-8 hours after PHA addition 
and continued to increase through the remainder of 
Table 2. Enzyme activity in mitogen stimulated peripheral lym- 
phocytes 
Hours b Activity a Total 
protein 
TPI LDH GPI p~g/10 7 
cells 
0 5.2 0.05 0.49 20.81 
6 14.8 0.52 1.60 74.15 
12 10.7 0.52 1.41 61.26 
18 12.9 0.61 1.25 64.25 
22 11.2 0.70 1.27 67.64 
26 12.5 0.94 1.52 78.11 
30 14.0 1.24 1.61 80.31 
36 12.9 1.06 1.34 72.17 
48 18.1 2.77 2.11 114.32 
p~mol product formed/min/107 ceils. 
b hours following addition of phytohemaggutinin M. TPI = 
Triosephosphate Isomerase; LDH = Lactate Dehydrogenase; 
GPI = Glucosephosphate Isomerase. 
the experiment. This increased LDH activity was 
associated with a change from predominantly the 
muscle type (LDHA) isozyme to predominantly 
the heart type (LDHB) isozyme (not shown). The 
phorbol ester, phorbol 12-myristate 13-acetate, 
either alone or in combination with PHA did not 
stimulate TPI-2 accumulation or the increase in 
TPI activity (data not shown). 
Inhibition studies 
The effects of agents that interfere with cell divi- 
sion at different stages of the cell cycle on the FCS 
stimulated accumulation of TPI activity in quies- 
cent fibroblasts are presented in Table 3. The in- 
hibitors were added concurrently with FCS. Dexa- 
methasone had its most significant effect at 24 
hours, inhibiting 90% of the FCS response; the 
activity was also reduced at 48 and 60 hours. Hy- 
droxyurea did not significantly affect the increase 
in TPI activity at the 24 hour time point but did 
inhibit the expected accumulation at 60 hours, 
probably reflecting decreased metabolic activity in 
cells where cell division is inhibited. The inhibition 
of the increase in TPI was reflected in the absence 
of the expected increase in the TPI 1/2 isozyme 
relative to the level of the TPI 1/1 isozyme. Fluo- 
rouridine, which inhibits RNA synthesis [35] 
(DNA synthesis would be inhibited at longer in- 
Table 3. Triosephosphate isomerase activity in stimulated hu- 
man fibroblasts 
Treatment Activity ~ 
24 hours b 60 hours b 
0.25% FCS 0.570 0.560 
20% FCS 1.380 1.460 
20% FCS + DEX 0.720 1.000 
20% FCS + HU 1.420 1.140 
20% FCS + FU 0.770 0.660 
a/zmol product formed/min/107 cells. 
bHours after addition of 20% FCS following 12 days of 0.25% 
FCS. FCS = Fetal Calf Serum; PHA = Phytohemaggluti- 
nin-M; D E X =  Dcxamethasone; HU = Hydroxyurea; F U =  
5-fluorouridine. 
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Fig. 3. Effects of inhibitors on TPI accumulation following mitogen stimulation of human tymphocytes. Peripheral lymphocytes were 
stimulated with phytohemagglutinin (PHA) 2.5 hours following addition of the inhibitor. Cells were harvested 0, 12, 24, or 48 hours 
after P H A  stimulation. Cell extracts were electrophoresed on a native polyacrylamide gel, which was then stained for TPI activity. 
Abbreviations: P H A  = Phytohemagglutinin-M, D E X  = Dexamethasone,  HU = Hydroxyurea, FU = 5-Fluorouridine, TK6 = hu- 
man lymphoblast,  Vero = African green monkey fibroblast. 
cubation times), inhibited > 80% of the expected 
response to FCS. The incomplete effectiveness of 
FU reflects the time necessary for equilibration 
with the cellular uridine pool [36]. 
The effects of the inhibitors on TPI activity and 
TPI-2 appearance in stimulated lymphocytes were 
similar to the results observed in the fibroblast 
experiments. TPI activity increased 2.5-fold by 12 
hours following mitogen addition and remained 
constant throughout the remainder of the time 
course in this experiment. Treatment of lympho- 
cytes with mitogen and dexamethasone prevented 
the increase in TPI activity observed with mitogen 
alone. At 48 hours following PHA addition, TPI 
activity in DEX plus PHA treated cells, was only 
30% of the activity in PHA alone treated cells and 
the increase in TPI-2 activity observed following 
PHA stimulation was almost completely inhibited 
by DEX treatment (Fig. 3). In hydroxyurea plus 
PHA treated lymphocytes, TPI activity at 12 and 24 
hours was > 70% of the level of activity in cells 
treated with PHA alone. The increase in TPI-2 
activity was not diminished by the addition of HU 
to the mitogen stimulated cells (Fig. 3). Twelve 
hours following addition of PHA to fiuorouridine 
treated cells, TPI activity was less than 50% that of 
PHA alone treated cells and was less than 30% of 
the activity in the mitogen cells at 48 hours. There 
was only a minimal appearance of TPI-2 in FU plus 
PHA treated cells. The level of TPI-2 in these cells 
was similar to the levels seen in cells with media 
alone (non-stimulated cells). 
TPI rnRNA studies 
A single primary species of TPI mRNA was detect- 
ed in human lymphocytes by northern blot analysis 
of RNA, although it is not possible to exclude the 
existence of additional mRNA species of similar 
size. This mRNA was approximately 1.2 kb in both 
dividing and non-dividing cells. This is the same 
size as previously reported [31] and is consistent 
with the size expected given the structure of the 
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Fig. 4. TPI mRNA accumulation in mitogen stimulated lympho- 
cytes. Total RNA was isolated from phytohemagglutinin 
(PHA) stimulated human lymphocytes. The RNA was treated 
with glyoxal, subjected to electrophoresis through a 1.1% aga- 
rose gel, transfered to GeneScreenPlus and hybridized with the 
human TPI cDNA probe. Shown is an overexposure of the 
autoradiogram. Lane 1 - 0 hours after PHA addition, lane 2 - 4 
hours after PHA addition, lane 3 - 8 hours after PHA addition, 
lane 4 - 12 hours after PHA addition, lane 5 - 18 hours after 
PHA addition, lane 6- 24 hours after PHA addition, lane 7- 50 
hours after PHA addition. 
human [24] and rhesus genes [37]. TPI mRNA was 
barely detectable in RNA isolated from nondivid- 
ing cells. Fig. 4 shows an overexposed autoradio- 
graph, where the TPI mRNA in unstimulated cells 
(0 time, lane 1) can be visualized. The additional, 
smaller mRNAs are presumably partially degraded 
TPI mRNA molecules and are only observed upon 
the 4-5 fold overexposure of the autoradiograph 
necessary to detect a band in lane 1. At 8 hours 
following P H A  stimulation of lymphocytes (lane 3) 
the level of TPI m RNA has increased at least sever- 
al fold. The TPI mRNA levels continue to increase, 
compared to total RNA, through the last time 
point in this experiment,  which is 50 hours. 
Only a single size TPI mRNA species was detec- 
table in human fibroblasts and it is the same size as 
observed in lymphoblasts. The pattern for TPI 
mRNA appearance during serum deprivation and 
subsequent serum restimulation of human fibro- 
blasts was similar to that observed for the TPI 1/2 
isozyme. The level of TPI mRN A  in quiescent 
fibroblasts was significantly reduced relative to 
confluent cells and was almost undetectable in qui- 
escent cells compared to the level in proliferating 
cells. At  20 hours following FCS stimulation, TPI 
m R N A  was at least twice the level detected in 
confluent cells and more than 10 times the level in 
quiescent cells. The TPI mRN A  returned to a level 
comparable to confluent cells at 36 and 52 hours 
following addition of FCS to quiescent fibroblasts. 
The cell growth factors, E G F  and FGF,  modulated 
TPI mRNA accumulation to an extent which was 
similar to the increase in TPI activity. 
The various agents which inhibited the mitogen 
stimulated increase in TPI activity and the expres- 
sion of TPI-2 also prevented the mitogen stimulat- 
ed accumulation of TPI mRNA. Analysis of dot 
blots of total RN A  from stimulated lymphocytes, 
probed for TPI mRNA,  showed that the TPI 
mRN A  level was less in cells treated with DEX 
plus PH A  than in cells treated with P H A  alone and 
was only slightly increased over that detected in 
unstimulated cells. H U  plus PH A  treatment did 
not significantly affect TPI mRN A  levels but FU 
plus P H A  drastically reduced TPI mRNA accumu- 
lation compared to TPI mRNA levels in cells treat- 
ed with PH A  alone. The pattern was exactly that 
observed for TPI 1/2 appearance. 
D N A  synthesis, as measured by [3H]-thymidine 
incorporation into trichloroacetic acid precipitated 
material, began at 30-36 hours following mitogen 
stimulation (data now shown). 
S1 nuclease mapping 
An autoradiogram of the S1 nuclease digestion pat- 
tern obtained with the EcoRI fragment of the 
cDNA is seen in Fig. 5. The EcoRI probe hybrid- 
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Fig. 5. $1 nuclease digestion analysis ofTPI mRNA. Total RNA 
isolated from a series of cells was hybridized to the EcoRI 
probe, the non-hybridizing segments were digested with S1 
nuclease and the samples electrophoresed as described in Meth- 
ods. A. Lane 1 - unstimulated peripheral human lymphocytes, 
lanes 2 and 3 are 24 and 48 hours after PHA stimulation of 
peripheral human lymphocytes, lane 4 - human lymphoblasts, 
lane 5 - human lymphoblasts from the TPI Manchester variant, 
lane 6 - human lymphoblast, lane 7 - no RNA control. B. Lane 1 
- no RNA control, lane 2 - 48 hours after PHA stimulation of 
human lymphocytes, lane 3 - human lyrnphoblast, lane 4 - vero 
fibroblast. The dark band in each figure is the protected frag- 
ment of the EcoRI probe (718 bp). 
izes with the entire coding region expected in the 
mature TPI mRNA,  except for the 32 bases at the 
3' end of the coding sequence, which are lacking in 
this probe. In panel A, lanes 1, 2, and 3 correspond 
to $1 nuclease digestions of RNA isolated from 
peripheral human lymphocytes of the same individ- 
ual at zero time (lane 1) and 24 hours (lane 2) or 48 
hours (lane 3) after initiation of mitogen (PHA) 
stimulation. Panel A is an overexposure of the film 
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(as compared to panel B) in order to detect the 
band in lane 1. As seen in panel B, the multiple 
minor bands are not observed without the over- 
exposure. These minor bands are presumably asso- 
ciated with hybridization to partially degraded 
mRNAs and/or 'nibbling' by the nuclease. The lev- 
el of TPI mRN A  dramatically increased in stim- 
ulated cells as was observed by northern analysis of 
the cells from the time course study. However  no 
primary bands were observed in the proliferating 
cells which were not also present in the mRNAs 
from cells prior to mitogen stimulation. Lanes 4, 5, 
and 6 are $1 digestions of RNAs isolated from 
several rapidly dividing transformed human lym- 
phoblastoid cell lines, cells which express high lev- 
els of TPI-2. Fig. 5B lane 4 is the result of an S1 
digestion of vero RN A  hybridized with the human 
EcoRI  cDNA fragment. The single protected frag- 
ment is the same size as is observed in R N A  from 
human cells. These data would exclude significant 
differences in mRN A  structure associated with dif- 
ferential mRN A  splicing between proliferating and 
nonproliferating human cells and also between hu- 
man and vero cells. 
Discussion 
The single structural locus for TPI located on hu- 
man chromosome 12 [24] encodes two electropho- 
retically distinct peptides [19, 23]. The expression 
of two subunits from a single gene for TPI is in 
contrast to several other glycolytic enzymes e.g. 
lactate dehydrogenase,  aldolase and pyruvate ki- 
nase where the different primary isoforms arise 
from distinct genes in a gene family [38-40] al- 
though pyruvate kinase also expresses two iso- 
zymes from each of the structural loci [38]. The 
TPI-1 and TPI-2 peptides (subunits) differ by one 
or more covalent modifications involving approxi- 
mately four charge units [20] which results in differ- 
ences in thermostability [19, 21] but no-kinetic 
properties [25]. These structural differences re- 
sponsible for the expression of the TPI-2 subunit 
are independent of the spontaneous deamidations 
of the labile asparagine residues [17, 20]. The TPI-1 
subunit is observed in a wide range of cells [18] 
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while TPI-2 is only observed in proliferating cells 
[19, 21, 22] derived from hominoid species (from 
human to gibbon) [17, 26]. The proliferation specif- 
ic, hominoid restricted subunit is detected in Chi- 
nese hamster ovary cells (which express only a 
constitutive hamster isozyme) which contain hu- 
man chromosome 12 as the only human chromo- 
some [41]. Thus, at least one of the critical pieces of 
information for the expression of the proliferation 
specific isozyme must be resident in the gene. That 
is, irrespective of the mechanism (alternative 
mRNA splice sites, amino acid residues which are 
potential substrates for modification, or some 
other mechanism) the primary transcript of the 
structural locus or subsequently the gene product 
must be the substrate for the modification. 
The TPI-2 subunit of TPI was detectable within 
6-10 hours following mitogen stimulation of human 
peripheral lymphocytes or serum restimulation of 
quiescent human fibroblasts. Total TPI activity in- 
creased 2.5 to 3.0-fold during the first 8-24 hours of 
stimulation with most of the increase associated 
with TPI-2. TPI-2 increased from almost undetec- 
table levels (< 5% of total activity) in quiescent 
peripheral lymphocytes to 3035% of the total ac- 
tivity in lymphocytes stimulated for 24 hrs with 
mitogen [20]. Only the constitutive TPI subunit 
was detectable in mitogen stimulated rabbit lym- 
phocytes or proliferating fibroblasts from the Afri- 
can green monkey (Vero) or other lower primates 
[17, 26]. 
As previously noted [21], TPI-2 expression was 
dependent upon RNA synthesis. This would be 
consistent with the absence of a precursor-product 
relationship between the subunits [20], unless ex- 
pression of TPI-2 was dependent upon de novo 
synthesis of an unidentified modifier enzyme which 
must also be located on human chromosome 12 to 
be consistent with the data from the human/ham- 
ster hybrid cell study. The expression of TPI-2 
before DNA synthesis would be consistent with an 
absence of significant inhibition of TPI-2 expres- 
sion by hydroxyurea, an agent which blocks DNA 
synthesis [42]. The absence of a requirement for 
DNA synthesis plus the observation that TPI-2 
expression occurs concurrently with TPI-1 expres- 
sion and is reversible argues against either gene 
duplication or rearrangement as a mechanism for 
TPI-2 expression. 
The inhibition of the mitogen stimulated in- 
crease in total TPI activity and TPI-2 expression by 
DEX has several implications. DEX presumably 
acts by inhibiting interleukin-2 (IL-2) production 
or interleukin-2 receptor expression [5, 43]. Thus, 
the increase in TPI activity and TPI-2 expression 
require early events in the T-cell activation se- 
quence which either involve IL-2 or are induced by 
IL-2 [6]. Inhibition of TPI-2 expression by cyclo- 
sporin A (Mohrenweiser, unpublished) would be 
consistent with the requirement for interleukin-2 
function [5, 7, 43]. Additionally, the inhibition of 
both TPI-2 expression and the increase in total TPI 
activity suggests that either these events are linked 
or that they are both responding to similar activa- 
tion signals. The expression of TPI-2 during cellu- 
lar proliferation has characteristics that are similar 
to the expression of several oncogenes and growth 
factors [3, 44, 45], except that TPI-2 results from 
apparently altered expression of an already active 
gene instead of expression of a previously inactive 
gene. It is noted that the apparent increase in TPI 
mRNA following stimulation of quiescent cells 
(approximately 10-fold or greater) is larger than 
the increase in total TPI activity (2-4 fold) in either 
lymphocytes or fibroblasts. 
Although the regulation of expression of TPI-2 
must be associated with early events in the G1 phase 
of cell proliferation [46], the mechanism for gener- 
ating the second subunit from the single structural 
locus is still undefined. Previous data have elim- 
inated a precursor-product relationship between 
the subunits [20] and the subunits do not differ 
significantly in molecular weight [20, 25]. The re- 
quirement for de novo protein synthesis for expres- 
sion of the TPI-2 subunit [21] would be consistent 
with the requirement for mRNA synthesis and also 
the absence of a precursor-product relationship be- 
tween the subunits. The requirement for mRNA 
synthesis would seem to also exclude, with the 
exception of a mechanism involving a linked (on 
human chromosome 12) modifier enzyme, differ- 
ential modification during nascent peptide synthe- 
sis. Additionally, neither subunit is phosphorylat- 
ed [47, 48], thus differential phosphorylation does 
account for the charge difference and preliminary 
results indicate that neither subunit is sulfated [48]. 
A relatively common mechanism for generating 
two (or more) proteins from a single structural 
locus involves differential processing of the pri- 
mary RNA transcript [49]. Many of these gene 
products exhibit tissue specific [50-53] and/or de- 
velopmental stage specific [54--57] expression. 
Thus, differential splicing can be a regulated pro- 
cess. However, TPI-2 expression exhibits neither 
developmental nor tissue specificity. Rather, it is 
regulated by, or a product of, cellular proliferation, 
and its expression is restricted to hominoid species. 
Only a single size species of TPI mRNA was detect- 
ed in either quiescent or proliferating cells and this 
mRNA was 1.2kb in both TPI-2 expressing and 
nonexpressing cells. Similarly, only a single TPI 
mRNA species could be detected by S1 nuclease 
analysis of RNA isolated from proliferating human 
cells, and the protected fragments were the same 
size in both quiescent and proliferating cells using a 
probe that includes all of the known splice junc- 
tions and all but 32 nucleotides at the 3' end of the 
coding region of the cDNA [37]. Vero cells do not 
express the TPI-2 subunit, thus, if differential 
mRNA processing is the mechanism for generating 
the TPI-2 subunit, vero should also exhibit, along 
with the sample from quiescent cells, an $1 nucle- 
ase digestion pattern for TPI mRNA which is less 
complex than the pattern observed in the prolifer- 
ating human lymphoblasts. This was not observed. 
Additional preliminary results with a probe that 
encompasses the 3' untranslated portion of the 
gene and the 3' half of the coding region, including 
310 nucleotides that overlap the EcoRI fragment 
cDNA probe, provide no indication of the exist- 
ence of different or multiple mRNA species in 
proliferating and nonproliferating human cells or 
differences in the mRNAs of human and veto cells 
in the region of the translation termination site or 
the 3' untranslated region (Old, unpublished ob- 
servations). No evidence of an additional, alterna- 
tive exon has been identified in either the sequence 
or restriction enzyme site map of the human [24] or 
rhesus [37] TPI genes. 
The functional TPI genes from two primate spe- 
cies, rhesus (Macaca rnulatta) which does not ex- 
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press a TPI-2 subunit and chimpanzee (Pan troglo- 
dytes) which expresses TPI-2, have been recently 
cloned and sequenced ([37] L. Craig, pers. com- 
mun). The human gene has also been previously 
sequenced [24]. The nucleotide sequence of the 
coding regions of rhesus and chimpanzee TPI genes 
are 98% identical and between rhesus and human 
the identity in nucleotide sequence is 97%. No 
amino acid differences are noted in comparing the 
derived enzyme sequences from chimp and human 
while the derived rhesus enzyme sequence differs 
from the chimp and human sequences by two resid- 
ues. The enzyme from rhesus has an asparagine 
residue instead of a serine at position 20 and a 
glutamic acid at position 198 instead of an aspartic 
acid. Although the serine in the hominoid enzyme 
is a potential site for several different covalent 
modifications, two of these (phosphorylation and 
sulfation) have already been excluded. Additional- 
ly, the presence of the serine does not correlate 
with the species restricted expression as a serine 
residue exists at this position in the enzyme of 
several other species, including the chicken [58], 
which does not express a second isozyme [17]. 
Inspection of the chimp gene provides no evi- 
dence for the existence of additional exons which 
could be possible substrates for alternative proces- 
sing and comparison of the nucleotide sequence of 
the gene from chimp and rhesus does not indicate 
sequences that would be suggestive of potential 
alternative splice sites in the chimp gene that are 
absent in the rhesus gene. These observations 
would be consistent with the absence of multiple 
mRNAs that are of sufficient difference to be de- 
tected by $1 nuclease mapping. 
Thus, although further insight into the regula- 
tion of the expression of the hominoid restricted, 
proliferation specific isozyme of TPI is presented, 
the mechanism for generation of the TPI-2 subunit 
remains elusive. 
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